Abstract:Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival for younger patients over the last several decades has improved nearly sixfold with the optimization of intensive induction chemotherapy and allogeneic stem cell transplantation (alloHSCT), this effect has been largely mitigated in older and less fit patients as well as those with adverse-risk disease characteristics. However, the last 10 years has been marked by major advances in the molecular profiling of AML characterized by a deeper understanding of disease pathobiology and therapeutic vulnerabilities. In this regard, the classification of AML subtypes has recently evolved from a morphologic to a molecular and genetic basis, reflected by recent updates from the World Health Organization and the new International Consensus Classification system. After years of stagnation in new drug approvals for AML, there has been a rapid expansion of the armamentarium against this disease since 2017. Low-intensity induction therapy with hypomethylating agents and venetoclax has substantially improved outcomes, including in those previously considered to have a poor prognosis. Furthermore, targeted oral therapies against driver mutations in AML have been added to the repertoire. But with an accelerated increase in treatment options, several questions arise such as how to best sequence therapy, how to combine therapies, and if there is a role for maintenance therapy in those who achieve remission and cannot undergo alloHSCT. Moreover, certain subtypes of AML, such as those with TP53 mutations, still have dismal outcomes despite these recent advances, underscoring an ongoing unmet need and opportunity for translational advances. In this review, we will discuss recent updates in the classification and risk stratification of AML, explore the literature regarding low-intensity and novel oral combination therapies, and briefly highlight investigative agents currently in early clinical development for high-risk disease subtypes.

Advances in Drug Delivery Systems for the Treatment of Acute Myeloid Leukemia

Nano-drug Delivery System for the Treatment of Acute Myelogenous Leukemia.

Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia

Recent advance in phytonanomedicine and mineral nanomedicine delivery system of the treatment for acute myeloid leukemia

Research Progress of Novel Drugs for Treatment of Acute Myeloid Leukemia

Advances in the Drug Therapies of Acute Myeloid Leukemia (except Acute Promyelocytic Leukemia)

Nanotechnology-assisted combination drug delivery: a progressive approach for the treatment of acute myeloid leukemia

The Potential for Clinical Translation of Antibody-Targeted Nanoparticles in the Treatment of Acute Myeloid Leukaemia

The Use of Nanocarriers in Acute Myeloid Leukaemia Therapy: Challenges and Current Status

Recent advances in targeted therapies in acute myeloid leukemia

Advances of Nanoparticles for Leukemia Treatment

Research Advances in Nanomedicine, Immunotherapy, and Combination Therapy for Leukemia.

[Advances of Targeted Therapy for Acute Myeloid Leukemia--Review].

Recent Advances in Material Technology for Leukemia Treatments

CAR-NK Cells for Acute Myeloid Leukemia Immunotherapy: Past, Present and Future.

Precision Therapy for Acute Myeloid Leukemia

The Landscape of Novel Strategies for Acute Myeloid Leukemia Treatment: Therapeutic Trends, Challenges, and Future Directions

Current and emerging molecular and epigenetic disease entities in acute myeloid leukemia and a critical assessment of their therapeutic modalities

Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic

Advances in pathogenesis research and challenges in treatment development for acute myeloid leukemia

Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective